Suxiao Jiuxin Pill (速效救心丸, SJP) is the first pure traditional Chinese medicine dripping pill officially recorded in the Pharmacopoeia of the People’s Republic of China. It is formulated with Chuanxiong (Chuanxiong Rhizoma) and Bingpian (Borneolum Syntheticum) as core components, and is clinically indicated for coronary heart disease and angina pectoris belonging to the qi stagnation and blood stasis syndrome, characterized by definite efficacy and rapid onset. Against the background that treatment of coronary heart disease emphasizes syndrome differentiation and individualized medication, the clinical demand for rapid-acting medicines for acute chest impediment has become increasingly prominent. This paper systematically reviews relevant domestic and international literatures, focusing on the key links of its “rapid onset” and the mechanism of “saving the heart”. From the perspectives of chemical constituents, formulation advantages, pharmacokinetic characteristics and molecular biological mechanisms, this review aims to explore the unique advantages of SJP and provide new ideas and theoretical references for its precise clinical application and further in-depth mechanistic research.

Suxiao Jiuxin Pill  /  rapid-onset mechanism  /  coronary heart disease  /  myocardial protection  /  qi stagnation and blood stasis